This proposal requests support for the continuation of a research training program in academic Gastroenterology that was established in 1999. The Program Director is Dr. Ciarn P Kelly, Professor of Medicine, Harvard Medical School (HMS) and Fellowship Program Director in Gastroenterology at Beth Israel Deaconess Medical Center (BIDMC). Continued support is requested for four trainee positions per year with each trainee spending two to three years in the training program. Trainees will have received an MD, PhD or MD-PhD degree and have a background in relevant scientific disciplines. The main criteria for selection will include educational achievements, demonstrated achievement and ability in biomedical research and a commitment to developing an academic career in research related to digestive disorders. Training will consist primarily of a mentored research program in health-related basic science, clinical research projects or translational research studies developed according to the needs, talents and career goals of the trainee. The main training site is the Gastroenterology and Hepatology Division at BIDMC. Additional BIDMC training sites will be in the Divisions of Endocrinology, Immunology, Nephrology, Systems Biology, Vaccines and Vascular Biology. External sites will be at the Harvard School of Public Health (Epidemiology & Biostatistics), the Veterans Administration (VA) Medical Center, Boston (Gastroenterology) and the Massachusetts General Hospital (MGH), (Pediatric Gastroenterology). A wide range of facilities and research cores are available at BIDMC, Harvard Medical School, the Harvard School of Public Health, the Boston VA and the MGH as well as through the Harvard Catalyst program (Harvard Clinical and Translational Science Award). All sites are situated in close proximity facilitating ongoing interactions. The T32 faculty performs GI-related research in many areas that can be grouped into four general themes: Liver Injury & Fibrosis, Infection & Immunity, Vascular Biology and Epithelial Biology. The cornerstone of the training program lies in the individual mentorship provided by our senior and accomplished faculty. This is augmented by a structured program of research seminars and lectures, journal clubs, laboratory presentations and ongoing career mentoring. Interested trainees will be encouraged to pursue advanced training including a Masters degree, if appropriate, (Masters in Public Health or Masters in Medical Science) or to take non-degree classes in areas important to their research career development. The central focus of the program is to enable talented and dedicated young scientists to advance their careers in academic medicine and eventually to become productive and independent investigators researching questions relevant to digestive health and disease.

Public Health Relevance

This program will address a critical issue in medicine, and especially in Gastroenterology, which is the dwindling supply of well-trained and productive physician-scientists and basic researchers focusing on GI and liver diseases. We will provide individual, mentored training programs and assistance in career development to highly talented and dynamic, physicians and scientists. Our ultimate goal is enable and to guide trainees so that they will compete successfully for funding that will allow them to develop careers as independent and productive researchers and faculty members at leading Universities, Laboratories and Medical Centers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Institutional National Research Service Award (T32)
Project #
2T32DK007760-16
Application #
8855078
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Densmore, Christine L
Project Start
1999-07-01
Project End
2020-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
16
Fiscal Year
2015
Total Cost
$253,642
Indirect Cost
$18,868
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Silvester, Jocelyn A; Faucher, Elizabeth A; McCarty, Caitlin E et al. (2018) Red Spot Lesions in the Duodenal Bulb are a Highly Specific Endoscopic Sign of Celiac Disease: A Prospective Study. J Pediatr Gastroenterol Nutr :
Ballou, S; Hirsch, W; Singh, P et al. (2018) Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Aliment Pharmacol Ther 47:913-921
Papamichael, Konstantinos; Vajravelu, Ravy K; Osterman, Mark T et al. (2018) Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci 63:761-767
Ballou, Sarah; Alhassan, Eaman; Hon, Elise et al. (2018) Sleep Disturbances Are Commonly Reported Among Patients Presenting to a Gastroenterology Clinic. Dig Dis Sci 63:2983-2991
Rangan, Vikram; Mitsuhashi, Shuji; Singh, Prashant et al. (2018) Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 16:1450-1458.e2
Juncadella, Anna; Papamichael, Konstantinos; Vaughn, Byron P et al. (2018) Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci :
Bollom, Andrea; Austrie, Jasmine; Hirsch, William et al. (2018) Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013. J Clin Gastroenterol 52:778-783
Fudman, David I; Papamichael, Konstantinos; Roemi, Lilach et al. (2018) Effect of Consent and Educational Adjuncts to Consent on Patient Perceptions About Colonoscopy. J Clin Gastroenterol :
Papamichael, Konstantinos; Cheifetz, Adam S (2017) Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol 23:6197-6200
Papamichael, Konstantinos; Chachu, Karen A; Vajravelu, Ravy K et al. (2017) Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol 15:1580-1588.e3

Showing the most recent 10 out of 62 publications